

EUDRACT NB: [2007-003728-39](#): A EUROPEAN MULTICENTER OPEN-LABEL RANDOMIZED TRIAL TO EVALUATE THE REDUCTION OF ISCHEMIA / REPERFUSION INJURY AFTER DE NOVO SIMULTANEOUS PANCREAS/KIDNEY TRANSPLANTATION IN TYPE 1-DIABETIC PATIENTS COMPARING A CONTROL GROUP VERSUS TREATMENT WITH PER-OPERATIVE N ACETYLCYSTEINE AND ANTITHROMBIN III VERSUS N ACETYLCYSTEINE ALONE .

That trial never started for the following reasons :

1. N Acetylcysteine (NACC) which is an old product, must be delivered free of charge by the pharmaceutical compagny, under its responsibility. That was necessitating changing the official indication for use without substantial profit for an old product. The owning pharmaceutical compagny cancelled its participation.
2. Even in countries where NACC might be used freely and had demonstrated benefit in a phase 2 mono center trial, none of other participants enrolled patients into the EuroSPK-003 study.
3. The initial major sponsor fund was dedicated for launching the study with all official requirements, but no local sponsoring for data management was rised and found.

Based on the above reasons, the EuroSPK Study Group was also dissolved.